Literature DB >> 26629281

Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death.

Loretta Fala.   

Abstract

Entities:  

Year:  2015        PMID： 26629281      PMCID： PMC4665045     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  7 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

3.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

4.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

5.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

6.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

7.  Fatal and nonfatal injuries involving fishing vessel winches--Southern shrimp fleet, United States, 2000-2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-03-08       Impact factor: 17.586
  7 in total
  3 in total

1.  HIV-1 Tat promotes astrocytic release of CCL2 through MMP/PAR-1 signaling.

Authors:  P Lorenzo Bozzelli; Tao Yin; Valeria Avdoshina; Italo Mocchetti; Katherine E Conant; Kathleen A Maguire-Zeiss
Journal:  Glia       Date:  2019-05-23       Impact factor: 7.452

2.  Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy.

Authors:  Kevin Bliden; Rahul Chaudhary; Athan Kuliopulos; Henry Tran; Hamid Taheri; Behnam Tehrani; Arnold Rosenblatt; Eliano Navarese; Udaya S Tantry; Paul A Gurbel
Journal:  J Thromb Haemost       Date:  2019-09-17       Impact factor: 5.824

Review 3.  Protease-Activated Receptors - Key Regulators of Inflammatory Bowel Diseases Progression.

Authors:  Damian Jacenik; Jakub Fichna; Ewa Małecka-Wojciesko; Anna Mokrowiecka
Journal:  J Inflamm Res       Date:  2021-12-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.